期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

11_β-羟基类固醇脱氢酶抑制剂的临床应用 被引量：4

下载PDF
导出
摘要 近年来,有研究发现11β-羟基类固醇脱氢酶可能参与了以2型糖尿病、肥胖、胰岛素抵抗、高血压等为主要表现的代谢综合征的病理生理过程,选择性的11β-羟基类固醇脱氢酶抑制剂很有可能成为治疗糖尿病、肥胖症等疾病的新药。本文就11β-HSD的作用1、1β-HSD抑制剂种类与作用等作一综述。
作者 梁菁菁 蒋戚
机构地区 解放军 第二军医大学研究生管理大队临床
出处 《东南国防医药》 2012年第2期149-151,共3页 Military Medical Journal of Southeast China
关键词 11Β-羟基类固醇脱氢酶 11β-羟基类固醇脱氢酶抑制剂 糖尿病 肥胖
分类号 R969 [医药卫生—药理学] R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献4

  • 1Stimson RH,Andrew R,McAvoy NC. Increased whole-body and sustained liver cortisol regeneration by 11 beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition[J].Diabetes,2011,(03):720-725.doi:10.2337/db10-0726.
  • 2Stewart PM,Whorwood CB. 11 beta-Hydroxysteroid dehydrogenase activity and corticosteroid hormone action[J].Steroids,1994,(02):90-95.doi:10.1016/0039-128X(94)90082-5.
  • 3孙国栋,范茂丹,周磊,杨敏,陆鸣.不同糖代谢状态疗养员动脉硬化检测结果及影响因素分析[J].东南国防医药,2011,13(3):236-238. 被引量：3
  • 4Edwards CR,Stewart PM,Burt D. Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor[J].The Lancet,1988,(8618):986-989.

二级参考文献5

共引文献2

同被引文献50

  • 1万小莉,任伟.11β-羟基类固醇脱氢酶1与2型糖尿病[J].重庆医学,2007,36(19):2016-2018. 被引量：4
  • 2Pereim CD, Azevedo I,Monteiro R,et al. 11 p-Hydroxysteroid de-hydrogenase type 1 : relevance of its modulation in the pathophysiol-ogy of obesity,the metabolic syndrome and type 2 diabetes mellitus[J]. Diabetes Obes Metab,2012,14(10) ;869-881.
  • 3Schnackenberg CG, Costell MH, Krosky DJ, et al. Chronic inhi-bition of 11 p -hydroxysteroid dehydrogenase type 1 activity de-creases hypertension,ipsulin resistance,and hypertriglyceridemiain metabolic syndrome [ J ]. Biomed Res Int, 2013, 2013 :427640.
  • 4A talar F, Gormez S, Caynak B,et al. Mediastinal adipose tissueexpresses a pathogenic profile of 11 p -hydroxysteroid dehydrogen-ase Type 1, glucocorticoid receptor, and CD68 in patients withcoronary artery disease [J]. Cardiovasc Pathol, 2013,22 (3 ):183-188.
  • 5Wamil M, Battle JH, Turban S, et al, Novel fat depot-specificmechanisms underlie resistance to visceral obesity and inflamma-tion in 11 p-hydroxysteroid dehydrogenase type 1 -deficient mice[J]. DiabeteSf2011 ,60(4)-1158-1167.
  • 6Bujalska U, Gathercole LL, Tomlinson JW, et al. A novel selec-tive 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor preventshuman adipogenesis [ J]. J Endocrinol,2008,197(2) :297-307.
  • 7Winnick JJ, Ramnanan CJ, Saraswathi V, et al. Effects of 11hydroxysteroid dehydrogenase-1 inhibition on hepatic glycogenolys-is and gluconeogenesis [ J ]. Am J Physiol Endocrinol Metab,2013,304(7):747-756.
  • 8Chapagain A, Caton PW, Kieswich J, et al. Elevated hepatic11 ^-hydroxysteroid dehydrogenase type 1 induces insulin resist-ance in uremia [ J]. Proc Natl Acad Sci U S A,2014,111(10):3817-3822.
  • 9Yoon DS, Wu SC, Seethala R, et al. Discovery of pyridyl sul-fonamide 11 -beta -hydroxysteroid dehydrogenase type 1 (11^-HSD1 ) inhibitor for the treatment of metabolic disorders [ J ].Bioorg Med Chem Lett,2014,24(21) :5045-5049.
  • 10Okazaki S, Takahashi T,Iwamura T, et al. HIS-388,a novel o-rally active and long-acting 11 ^-hydroxysteroid dehydrogenasetype 1 inhibitor, ameliorates insulin sensitivity and glucose intol-erance in diet-induced obesity and nongenetic type 2 diabetic mu-rine models [ J]. J Pharmacol Exp Ther,2014,351 (1) ; 181-189.

引证文献4

二级引证文献16

东南国防医药
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部